<?xml version='1.0' encoding='utf-8'?>
<document id="23254426"><sentence text="Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients."><entity charOffset="92-101" id="DDI-PubMed.23254426.s1.e0" text="efavirenz" /></sentence><sentence text="Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable"><entity charOffset="136-145" id="DDI-PubMed.23254426.s2.e0" text="efavirenz" /></sentence><sentence text=" A total of 139 HIV/TB adults, 101 of whom received a rifampin-containing anti-TB regimen, were prospectively enrolled to receive efavirenz (600 mg)/tenofovir/lamivudine"><entity charOffset="54-62" id="DDI-PubMed.23254426.s3.e0" text="rifampin" /><entity charOffset="130-139" id="DDI-PubMed.23254426.s3.e1" text="efavirenz" /><entity charOffset="149-158" id="DDI-PubMed.23254426.s3.e2" text="tenofovir" /><entity charOffset="159-169" id="DDI-PubMed.23254426.s3.e3" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e0" e2="DDI-PubMed.23254426.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e0" e2="DDI-PubMed.23254426.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e0" e2="DDI-PubMed.23254426.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e0" e2="DDI-PubMed.23254426.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e1" e2="DDI-PubMed.23254426.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e1" e2="DDI-PubMed.23254426.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e1" e2="DDI-PubMed.23254426.s3.e3" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e2" e2="DDI-PubMed.23254426.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23254426.s3.e2" e2="DDI-PubMed.23254426.s3.e3" /></sentence><sentence text=" Nine single nucleotide polymorphisms (SNPs) within CYP2B6 were genotyped" /><sentence text=" Plasma efavirenz concentrations were measured at 12 weeks"><entity charOffset="8-17" id="DDI-PubMed.23254426.s5.e0" text="efavirenz" /></sentence><sentence text=" The median (interquartile range [IQR]) efavirenz concentration was 2"><entity charOffset="40-49" id="DDI-PubMed.23254426.s6.e0" text="efavirenz" /></sentence><sentence text="3 (1" /><sentence text="4 to 3" /><sentence text="9) mg/liter" /><sentence text=" The SNPs (frequencies of heterozygous and homozygous mutants) were 64C&gt;T (10% and 1%), 499C&gt;G (0% and 0%), 516G&gt;T (47% and 8%), 785A&gt;G (54% and 10%), 1375A&gt;G (0% and 0%), 1459C&gt;T (3% and 0%), 3003C&gt;T (44% and 27%), 18492T&gt;C (39% and 6%), and 21563C&gt;T (57% and 5%)" /><sentence text=" The four most frequent CYP2B6 haplotypes identified were *1/*6 (41%), *1/*1 (35%), *1/*2 (7%), and *6/*6 (7%)" /><sentence text=" The heterozygous/homozygous mutation associated with low efavirenz concentrations was 18492T&gt;C (P &lt; 0"><entity charOffset="58-67" id="DDI-PubMed.23254426.s12.e0" text="efavirenz" /></sentence><sentence text="001), and those associated with high efavirenz concentrations were 516G&gt;T, 785A&gt;G, and 21563C&gt;T (all P &lt; 0"><entity charOffset="37-46" id="DDI-PubMed.23254426.s13.e0" text="efavirenz" /></sentence><sentence text="05)" /><sentence text=" Haplotype *1/*1 was associated with low efavirenz concentrations, and *6/*6, *1/*6, and *5/6 were associated with high efavirenz concentrations"><entity charOffset="41-50" id="DDI-PubMed.23254426.s15.e0" text="efavirenz" /><entity charOffset="120-129" id="DDI-PubMed.23254426.s15.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23254426.s15.e0" e2="DDI-PubMed.23254426.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23254426.s15.e0" e2="DDI-PubMed.23254426.s15.e1" /></sentence><sentence text=" As shown by multivariate analysis, low efavirenz concentrations were significantly associated with the *1/*1 haplotype (beta = -1"><entity charOffset="40-49" id="DDI-PubMed.23254426.s16.e0" text="efavirenz" /></sentence><sentence text="084, P = 0" /><sentence text="027) and high body weight (beta = -0" /><sentence text="076, P = 0" /><sentence text="002)" /><sentence text=" In conclusion, pharmacogenetic markers of CYP2B6 have the greatest impact with respect to inducing low plasma efavirenz concentrations in HIV/TB Thai patients"><entity charOffset="111-120" id="DDI-PubMed.23254426.s21.e0" text="efavirenz" /></sentence><sentence text="" /></document>